Group items matching

in title, tags, annotations or url

Copper Control as an Antiangiogenic Anticancer Therapy: Lessons from Treating Wilson's Disease -- Brewer 226 (7): 665 -- Experimental Biology and Medicine

WARNING: This page was NOT created or approved by any doctor or medical researcher. The purpose of this page is to provide hard-to-find information on copper reduction cancer treatment, a new unapproved and experimental course of cancer treatment whose ef

Vitamin D deficiency and risk of cardiovascular disease. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS. Circulation. 2008 Jan 29;117(4):503-11. Epub 2008 Jan 7. PMID: 18180395 doi: 10.1161/CIRCULATIONAHA.107.706127 Conclusions- Vitamin D deficiency is associated with incident cardiovascular disease. Further clinical and experimental studies may be warranted to determine whether correction of vitamin D deficiency could contribute to the prevention of cardiovascular disease.

Vitamin D treatment in multiple sclerosis. Myhr KM. J Neurol Sci. 2009 Jun 22. [Epub ahead of print] PMID: 19549608 doi:10.1016/j.jns.2009.05.002 Epidemiological evidence combined with clinical and laboratory analyses, and experimental animal models, suggest a possible influence of vitamin D on MS susceptibility as well as clinical disease activity. Supplement with vitamin D may reduce the risk of developing MS. An intervention may also reduce the risk of conversion from a first clinical event suggestive of MS to clinical definite MS, as well as reduce the relapse rate among patients with relapsing remitting MS. More studies are, however, needed to determine optimal dose and serum level for vitamin D, as well as target populations and optimal timing for intervention.

Vitamin D status and the risk of lung cancer: a cohort study in Finland. Kilkkinen A, Knekt P, Heliövaara M, Rissanen H, Marniemi J, Hakulinen T, Aromaa A. Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3274-8. PMID: 18990771v In conclusion, although there was no overall association between vitamin D and lung cancer risk, women and young participants with a higher level of vitamin D were observed to have a lower lung cancer risk. Although experimental data support the suppressing effect of vitamin D on the development of lung cancer, large epidemiologic studies from different populations with repeated measurements of vitamin D are warranted to confirm this finding. (Cancer Epidemiol Biomarkers Prev 2008;17(11):3274-8)

A positive association of lumbar spine bone mineral density with dietary protein is suppressed by a negative association with protein sulfur. Thorpe M, Mojtahedi MC, Chapman-Novakofski K, McAuley E, Evans EM. J Nutr. 2008 Jan;138(1):80-5. PMID: 18156408 Results suggest that protein intake is positively associated with aBMD, but benefit at the LS is offset by a negative impact of the protein sulfur acid load. If validated experimentally, these findings harmonize conflicting theories on the role of dietary protein in bone health.

March 7, 2005 Boston, MA - The anti-inflammatory effect of fish oils appears to be due to a powerful anti-inflammatory compound called resolvin (resolution-phase interaction product) E1, which is produced from eicosapentaenoic acid (EPA), Dr Makoto Arita (Brigham and Women's Hospital and Harvard Medical School, Boston, MA) and colleagues report in the March 7, 2005 issue of the Journal of Experimental Medicine [1]. Arita writes, "At nanomolar levels, resolvin E1 dramatically reduced dermal inflammation, peritonitis, dendritic cell migration, and interleukin (IL)-12 production.

(NaturalNews) Adequate levels of vitamin K play in a central role in the development and maintenance of healthy bones in children, according to a study conducted by Dutch researchers from the Universities of Maastricht and Utrecht and published in the journal Clinical and Experimental Rheumatology.

ScienceDaily (Sep. 9, 2006) - An experimental anti-cancer regimen combined a diuretic, a Parkinson's disease medication and a drug ordinarily used to reverse the effect of sedatives. In research conducted at Washington University School of Medicine in St. Louis, the unusual mixture inhibited the growth of aggressive prostate tumors in laboratory mice.

Are omega-3 fatty acids options for prevention and treatment of cognitive decline and dementia? Cederholm T, Palmblad J. Curr Opin Clin Nutr Metab Care. 2009 Dec 16. [Epub ahead of print] PMID: 20019606 PURPOSE OF REVIEW: To report recent data on the potential role of omega-3 fatty acids (n-3 FA) found in oily fish, especially docosahexaenoic acid (DHA), to prevent and treat cognitive decline and Alzheimer's disease. RECENT FINDINGS: Observational studies still provide conflicting results, in which the majority indicate beneficial effects on cognition, both when assessed as a continuous variable or as incident dementia, mainly Alzheimer's disease. Experimental studies have demonstrated potentially ameliorating effects of eicosapentaenoic acid (EPA) and DHA on amyloid fragment formation, signal transduction including upregulation of the apolipoprotein receptor SorLA, as well as on angiogenesis. The role of EPA and DHA metabolites on Alzheimer's disease pathology is under investigation. Recently, three randomized intervention studies, with duration up to 6 months have been reported. In contrast to a small study from Taiwan, no positive overall effects were reported from the Swedish OmegAD Study or from a Dutch study, although post hoc analyses indicate that selected individuals with mild forms of Alzheimer's disease or cognitive decline may respond to treatment. SUMMARY: No firm conclusions can be drawn. Based on epidemiological data, fish including oily fish could be advised as part of a balanced diet for public health purpose, although the evidence for better cognition is only fairly consistent. It is unlikely that n-3 FA will emerge as a treatment option in general for improving cognitive function in patients with Alzheimer's disease. n-3 FA, especially DHA, may turn out as an adjuvant therapy in selected cases. Further long-term intervention studies on individuals with mild cognitive reductions are awaite"

"(NaturalNews) New research published in The Journal of the Federation of American Societies for Experimental Biology (FASEB) has found that the "Western" diet, typically high in sugar and fat, may be responsible for activating genes that signal the body to become fatter. According to scientists, the body's response to high amounts of energy-dense food is to activate the kappa opioid receptor which triggers increased fat storage. Researchers arrived at this conclusion by conducting an experiment on two groups of mice. One group had its kappa opioid receptors genetically deactivated while the other remained intact. Both groups were fed diets high in fat and sugar for 16 weeks. At the end of 16 weeks, the group with the deactivated receptor remained lean while the control group gained significant weight. Besides limiting their bodies' ability to store energy-dense food in their fat stores, the mice whose receptors had been deactivated were noted to also have a limited ability to assimilate and store nutrients from the foods they ingested. Traci Ann Czyzyk-Morgan, one of the study's researchers, indicated that the findings prove the hypothesis long held by many in the scientific community that the kappa opioid receptor may be responsible for causing widespread obesity in Western countries. She and others continue to encourage people to avoid diets high in fat and sugar. "

"The "Selfish Brain" theory describes the characteristic of the human brain to cover its own, comparably high energy requirements with the utmost of priorities when regulating energy fluxes in the organism. The brain behaves selfishly in this respect. The "Selfish brain" theory amongst other things provides a novel explanation for the origin of obesity, the severe and pathological form of overweight. The Luebeck obesity and diabetes specialist Achim Peters developed the fundamentals of this theory between 1998 and 2004. The interdisciplinary "Selfish Brain: brain glucose and metabolic syndrome" research group headed by Peters and supported by the German Research Foundation (DFG) at the University of Luebeck has in the meantime been able to reinforce the basics of the theory through experimental research. Scientists the world over now consider this work as pioneering for the study of the causes of pathological eating disorders and the development of innovative therapies."

Vitamin D deficiency and risk of cardiovascular disease. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS. Circulation. 2008 Jan 29;117(4):503-11. Epub 2008 Jan 7. PMID: 18180395 doi: 10.1161/CIRCULATIONAHA.107.706127 Conclusions-Vitamin D deficiency is associated with incident cardiovascular disease. Further clinical and experimental studies may be warranted to determine whether correction of vitamin D deficiency could contribute to the prevention of cardiovascular disease.

"Berberine is a quaternary ammonium salt from the group of isoquinoline alkaloids. It is found in such plants as Berberis, goldenseal (Hydrastis canadensis), and Coptis chinensis, usually in the roots, rhizomes, stems, and bark. Berberine is strongly yellow colored, which is why in earlier times berberis species were used to dye wool, leather and wood. Wool is still today dyed with berberine in Northern India Berberine (BBR) is a natural compound with up-regulating activity on both low-density-lipoprotein receptor (LDLR) and insulin receptor (InsR). This one-drug-multiple-target characteristic might be suitable for the treatment of metabolic syndrome.[12] Berberine has been tested and used successfully in experimental[13] and human diabetes mellitus.[14][15][16] Berberine has been shown to lower elevated blood glucose as effectively as metformin.[17] The mechanisms include inhibition of aldose reductase,[18] inducing glycolysis,[19] preventing insulin resistance[20] through increasing insulin receptor expression[14] and acting like incretins. Berberine has drawn extensive attention towards its antineoplastic effects.[43][44] It seems to suppress the growth of a wide variety of tumor cells including breast cancer,[45] leukemia, melanoma,[46] epidermoid carcinoma, hepatoma, oral carcinoma, tongue carcinoma,[47] glioblastoma, prostate carcinoma, gastric carcinoma.[48][49] Animal studies have shown that berberine can suppress chemical-induced carcinogenesis, tumor promotion, tumor invasion,[50][51][52][53][54] prostate cancer,[55][56][57][58] neuroblastoma,[59][60] and leukemia.[34][61] It is a radiosensitzer of tumor cells but not of normal cells

A review of scientific research and recommendations regarding eggs. Kritchevsky SB. J Am Coll Nutr. 2004 Dec;23(6 Suppl):596S-600S. Review. PMID: 15640512 For much of the past 40 years, the public has been warned away from eggs because of a concern over coronary heart disease risk. This concern is based on three observations: 1. eggs are a rich source of dietary cholesterol; 2. when fed experimentally, dietary cholesterol increases serum cholesterol and; 3. high serum cholesterol predicts the onset of coronary heart disease. However, data from free-living populations show that egg consumption is not associated with higher cholesterol levels. Furthermore, as a whole, the epidemiologic literature does not support the idea that egg consumption is a risk factor for coronary disease. Within the nutritional community there is a growing appreciation that health derives from an overall pattern of diet rather than from the avoidance of particular foods, and there has been a shift in the tone in recent dietary recommendations away from "avoidance" messages to ones that promote healthy eating patterns. The most recent American Heart Association guidelines no longer include a recommendation to limit egg consumption, but recommend the adoption of eating practices associated with good health. Based on the epidemiologic evidence, there is no reason to think that such a healthy eating pattern could not include eggs.

The controversial place of vitamin C in cancer treatment. Verrax J, Calderon PB. Biochem Pharmacol. 2008 Dec 15;76(12):1644-52. Epub 2008 Sep 30. Review. PMID: 18938145 doi:10.1016/j.bcp.2008.09.024    

A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. Riordan HD, Casciari JJ, González MJ, Riordan NH, Miranda-Massari JR, Taylor P, Jackson JA. P R Health Sci J. 2005 Dec;24(4):269-76. PMID: 16570523

Intravenous vitamin C as a chemotherapy agent: a report on clinical cases.\nRiordan HD, Riordan NH, Jackson JA, Casciari JJ, Hunninghake R, González MJ, Mora EM, Miranda-Massari JR, Rosario N, Rivera A.\nP R Health Sci J. 2004 Jun;23(2):115-8.\nPMID: 15377059

Intravenously administered vitamin C as cancer therapy: three cases.\nPadayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M.\nCMAJ. 2006 Mar 28;174(7):937-42.\nPMID: 16567755 \ndoi:10.1503/cmaj.050346.